Study	O
arms	O
and	O
treatment	O
plans	O

Patients	O
were	O
randomly	O
divided	O
into	O
two	O
treatment	O
groups	O
,	O
a	O
case	O
group	O
comprising	O
56	O
patients	O
and	O
a	O
control	O
group	O
comprising	O
55	O
patients	O
.	O

On	O
the	O
first	O
day	O
of	O
admission	O
,	O
laboratory	O
studies	O
including	O
complete	B-OtherOutcome
blood	I-OtherOutcome
count	I-OtherOutcome
and	O
erythrocyte	B-OtherOutcome
sedimentation	I-OtherOutcome
rate	I-OtherOutcome
(	I-OtherOutcome
ESR	I-OtherOutcome
)	I-OtherOutcome
were	O
performed	O
.	O

The	O
case	O
group	O
received	O
oral	O
AZM	O
500	O
mg	O
daily	O
,	O
oral	O
LPV	O
/	O
r	O
400	O
/	O
100	O
mg	O
twice	O
daily	O
and	O
oral	O
HCQ	O
400	O
mg	O
daily	O
.	O

The	O
control	O
group	O
received	O
oral	O
LPV	O
/	O
r	O
400	O
/	O
100	O
mg	O
twice	O
daily	O
and	O
oral	O
HCQ	O
400	O
mg	O
daily	O
;	O
for	O
both	O
treatment	O
groups	O
,	O
all	O
medications	O
were	O
administered	O
for	O
5	O
days	O
.	O

On	O
the	O
first	O
day	O
of	O
admission	O
,	O
for	O
patients	O
assigned	O
to	O
the	O
case	O
treatment	O
group	O
,	O
the	O
risk	B-OtherOutcome
for	I-OtherOutcome
ventricular	I-OtherOutcome
arrhythmia	I-OtherOutcome
in	O
concurrent	O
treatment	O
with	O
HCQ	O
and	O
AZM	O
was	O
calculated	B-OutcomeDefinition
based	I-OutcomeDefinition
on	I-OutcomeDefinition
the	I-OutcomeDefinition
proposed	I-OutcomeDefinition
guideline	I-OutcomeDefinition
by	I-OutcomeDefinition
the	I-OutcomeDefinition
ACC	I-OutcomeDefinition
[	I-OutcomeDefinition
23	I-OutcomeDefinition
]	I-OutcomeDefinition
,	I-OutcomeDefinition
and	I-OutcomeDefinition
patients	I-OutcomeDefinition
with	I-OutcomeDefinition
a	I-OutcomeDefinition
score	I-OutcomeDefinition
of	I-OutcomeDefinition
≥	I-OutcomeDefinition
7	I-OutcomeDefinition
were	I-OutcomeDefinition
excluded	I-OutcomeDefinition
from	I-OutcomeDefinition
the	I-OutcomeDefinition
study	I-OutcomeDefinition
.	O

Patients	O
were	O
assessed	O
by	O
daily	B-TimeFrame
measurements	I-TimeFrame
of	O
core	B-OtherOutcome
body	I-OtherOutcome
temperature	I-OtherOutcome
,	O
respiratory	B-OtherOutcome
rate	I-OtherOutcome
,	O
heart	B-OtherOutcome
rate	I-OtherOutcome
and	O
peripheral	B-OtherOutcome
capillary	I-OtherOutcome
oxygen	I-OtherOutcome
saturation	I-OtherOutcome
(	I-OtherOutcome
SpO2	I-OtherOutcome
)	I-OtherOutcome
.	O

Daily	B-TimeFrame
electrocardiogram	B-OtherOutcome
(	I-OtherOutcome
ECG	I-OtherOutcome
)	I-OtherOutcome
studies	O
were	O
also	O
conducted	O
to	O
monitor	O
possible	O
evolution	B-OutcomeDefinition
of	I-OutcomeDefinition
heart	I-OutcomeDefinition
rate	I-OutcomeDefinition
-	I-OutcomeDefinition
corrected	I-OutcomeDefinition
QT	I-OutcomeDefinition
(	I-OutcomeDefinition
QTc	I-OutcomeDefinition
)	I-OutcomeDefinition
interval	I-OutcomeDefinition
prolongation	I-OutcomeDefinition
,	O
in	O
which	O
case	O
,	O
treatment	O
with	O
AZM	O
and	O
HCQ	O
would	O
have	O
been	O
stopped	O
.	O

For	O
correction	O
of	O
the	O
QT	O
interval	O
,	O
Bazett	O
'	O
s	O
formula	O
(	O
QTc	O
=	O
QT	O
/	O
√	O
RR	O
)	O
was	O
used	O
[	O
24	O
]	O
.	O

In	O
case	O
of	O
deterioration	O
in	O
general	O
and	O
/	O
or	O
pulmonary	O
condition	O
,	O
methylprednisolone	O
was	O
prescribed	O
[	O
25	O
]	O
.	O

Patients	O
were	O
discharged	O
when	O
they	O
achieved	O
a	O
stable	O
SpO2	O
>	O
92	O
%	O
,	O
had	O
no	O
respiratory	O
distress	O
and	O
were	O
afebrile	O
for	O
3	O
consecutive	O
days	O
.	O

The	O
primary	O
endpoints	O
in	O
this	O
trial	O
were	O
a	O
decrease	B-PrimaryOutcome
in	I-PrimaryOutcome
mortality	I-PrimaryOutcome
,	O
duration	B-PrimaryOutcome
of	I-PrimaryOutcome
hospitalisation	I-PrimaryOutcome
and	O
need	B-PrimaryOutcome
for	I-PrimaryOutcome
intensive	I-PrimaryOutcome
care	I-PrimaryOutcome
unit	I-PrimaryOutcome
(	I-PrimaryOutcome
ICU	I-PrimaryOutcome
)	I-PrimaryOutcome
admission	I-PrimaryOutcome
.	O

Secondary	O
endpoints	O
were	O
determined	O
as	O
improvements	B-SecondaryOutcome
in	I-SecondaryOutcome
SpO2	I-SecondaryOutcome
and	I-SecondaryOutcome
vital	I-SecondaryOutcome
signs	I-SecondaryOutcome
as	O
well	O
as	O
the	O
general	B-SecondaryOutcome
wellbeing	I-SecondaryOutcome
of	I-SecondaryOutcome
the	I-SecondaryOutcome
patient	I-SecondaryOutcome
.	O

Sample	O
size	O
calculation	O
was	O
performed	O
for	O
non	O
-	O
inferiority	O
tests	O
of	O
difference	O
between	O
two	O
group	O
proportions	O
.	O

We	O
assumed	O
an	O
effectiveness	O
of	O
65	O
%	O
for	O
the	O
intervention	O
group	O
and	O
effectiveness	O
of	O
50	O
%	O
for	O
the	O
control	O
group	O
.	O

We	O
also	O
assumed	O
a	O
margin	O
of	O
non	O
-	O
inferiority	O
of	O
at	O
least	O
10	O
%	O
between	O
the	O
two	O
groups	O
.	O

With	O
these	O
assumptions	O
,	O
a	O
sample	O
size	O
of	O
48	O
cases	O
in	O
each	O
group	O
was	O
calculated	O
.	O

After	O
consideration	O
of	O
a	O
dropout	O
rate	O
of	O
10	O
%	O
,	O
the	O
total	O
sample	O
size	O
of	O
110	O
cases	O
was	O
calculated	O
.	O

The	O
power	O
of	O
the	O
study	O
was	O
determined	O
as	O
90	O
%	O
(	O
G	O
*	O
Power	O
,	O
Erdfelder	O
,	O
Faul	O
,	O
&	O
Buchner	O
,	O
1996	O
)	O
.	O

